
    
      A randomized, multi-center, double-blinded study in subjects with moderate to severe acne
      vulgaris. Subjects eligible to enroll will be treated once or twice daily with 2
      concentrations of a topical drug in development or a vehicle. Subjects will be treated for up
      to 12 weeks.
    
  